JKT · KLBF.JK
PT Kalbe Farma Tbk.
IDR 730+IDR 15 (+2.1%)
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
Loading market information…
JKT · PYFA.JK · IDR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · IDR. Historical prices are not a forecast.
PT Pyridam Farma Tbk’s quoted price sits in the lower half of its reported 52-week range, 78.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PT Pyridam Farma Tbk’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the development, production, and distribution of a broad spectrum of health-related products. Its offerings encompass pharmaceuticals, antibiotics, essential vitamins, dietary supplements, and traditional herbal remedies. The company's operations are divided into two main segments: Pharmaceutical Products and Contract Manufacturing Services, and Medical Device Products. Within its medical device division, the firm provides a variety of instruments and consumables. These include clinical waste management items, collection swabs and tubes, innerbox DCA, KF94 masks, parafilm, PCR extraction kits and their accompanying machinery, specimen bags, sterile containers, and tube stoppers. Furthermore, PT Pyridam Farma markets a diverse collection of skincare products, such as Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel. Its pharmaceutical portfolio addresses numerous therapeutic areas, including digestive and metabolic health, blood and blood-forming organ conditions, cardiovascular disorders, dermatological ailments, genitourinary system and sex hormone regulation, systemic corticosteroids, systemic antibacterial treatments, sensory organ issues, as well as musculoskeletal, nervous, and respiratory system conditions. Beyond medicinal lines, the company also develops and sells dietary supplements and preventive consumer health items, notably energy drinks and various healthy ready-to-consume beverages. A key area of its strategic focus involves conducting extensive research and development in biotechnology, life sciences, and medical science. Established in 1976, PT Pyridam Farma Tbk is headquartered in Jakarta, Indonesia.
Latest available per-share figures in IDR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 730+IDR 15 (+2.1%)
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
IDR 1,100-IDR 60 (-5.17%)
PT SOHO Global Health Tbk.’s quoted price sits in the lower half of its reported 52-week range, 72.57% below the high.
IDR 324+IDR 2 (+0.62%)
PT Industri Jamu dan Farmasi Sido Muncul Tbk’s quoted price sits in the lower half of its reported 52-week range, 44.62% below the high.
IDR 185-IDR 5 (-2.63%)
PT Jayamas Medica Industri Tbk’s quoted price sits in the lower half of its reported 52-week range, 41.82% below the high.
IDR 1,150+IDR 65 (+5.99%)
PT Mark Dynamics Indonesia Tbk’s quoted price sits in the upper half of its reported 52-week range, 9.09% below the high.
IDR 338-IDR 20 (-5.59%)
PT Kimia Farma (Persero) Tbk’s quoted price sits in the lower half of its reported 52-week range, 56.94% below the high.
IDR 1,570IDR 0 (0.0%)
PT Darya-Varia Laboratoria Tbk’s quoted price sits in the upper half of its reported 52-week range, 7.37% below the high.
IDR 3,610IDR 0 (0.0%)
PT Merck Tbk’s quoted price sits in the lower half of its reported 52-week range, 19.78% below the high.
